General Characteristics of Bone Marrow Failure and Aplastic Anemia

General Characteristics of Bone Marrow (BM)

  • Definition of Sycytopenia

    • Sycytopenia is characterized by a deficiency in blood cell formation due to hypocellular bone marrow (BM).
    • Impacts all three cell lines leading to pancytopenia, as seen in constitutional aplastic anemia.
    • Affects two cell lines, similar to paroxysmal nocturnal hemoglobinuria (PNH).
    • Focuses on a single blood cell line, for instance, in Diamond-Blackfan anemia (DBA).

  • Clinical Implications of Cytopenia

    • Cytopenias associated with hypocellular marrows may arise from:
    • Premalignant conditions.
    • Myelofibrosis.

Laboratory Findings in Bone Marrow Failure Syndromes

  • Cytopenia Characteristics
    • Presents with a wide range of cytopenias which can be mild to severe.
    • The phenomenon of macrocytosis may be evident, potentially being the sole finding.
    • May be obscured by an underlying condition like iron deficiency or thalassemia.
    • Elevated hemoglobin F (Hgb F) levels are regularly observed.
    • Dysplastic changes in bone marrow cells include:
    • Micromegakaryocytes.
    • Pseudo-Pelger-Huet anomalies.
    • Mild nuclear-cytoplasmic (N:C) asynchrony.
    • Multinucleated normoblastic precursors.

Acquired Aplastic Anemia

  • Overview
    • Aplastic anemia is recognized as a rare disease of bone marrow failure.
    • Major form, idiopathic aplastic anemia, occurs in patients without a clear history of:
    • Chemical or drug exposure.
    • Viral infection.
    • Other types include:
    • Iatrogenic aplastic anemia (induced by medical treatment).
    • Constitutional aplastic anemia (genetic predisposition to BM failure).

Clinical Features of Aplastic Anemia

  • Symptomatology

    • Signs and symptoms vary according to the severity of deficiencies:
    • Bleeding due to thrombocytopenia.
    • Increased susceptibility to infections resulting from neutropenia.
    • Symptoms associated with anemia.
    • Splenomegaly and lymphadenopathy are not typically present.

  • Long-term Prognosis

    • Survivors of acquired aplastic anemia face heightened risks for:
    • Malignancies (both leukemic and solid tumors) later in life after achieving remission.
    • Specific risks include:
      • 9% chance of developing PNH.
      • 16% chance of developing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Laboratory Findings in Aplastic Anemia

  • Cell Line Involvement

    • If all cell lines are impacted, the condition is termed pancytopenia.
    • If predominantly one line is affected, it is commonly the erythrocytic line.

  • Diagnostic Criteria

    • Diagnosis is considered when at least two out of three peripheral blood (PB) values fall below critical thresholds.
    • Red blood cells (RBCs) are typically normocytic and normochromic:
    • May present varying degrees of anisocytosis (size variation).
    • Poikilocytosis (shape variation) present with normal red cell distribution width (RDW).
    • Those with a genetic component may show TERT or TERC telomerase mutations in approximately 5% to 10% of patients.

Treatment Options for Aplastic Anemia

  • Response to Therapies

    • Aplastic anemia can respond positively to immunosuppressive therapy.
    • Factors influencing success include:
    • Extent of organ damage.
    • Tissue regeneration capacity.
    • Appropriate drug regimen to manage an intense immune response that is often misdirected.

  • Evolving Treatment Outcomes

    • Historically regarded as almost universally fatal, aplastic anemia is now manageable via:
    • Stem cell transplantation.
    • Immunosuppressive drug therapy, which can result in cure or significant amelioration of the disease.